Novo Nordisk

Pharma

Eli Lilly's Zepbound preferred by physicians: Spherix survey

A Spherix survey of physicians shows that injected weight loss drugs remain favored over newer oral treatments, with Lilly’s Zepbound leading the pack

Kevin Dunleavy Aug 7, 2026 11:36am

showdown clash versus vs crash lightning fight dispute

The Oral GLP-1 Tracker: Lilly's Foundayo builds scripts

Aug 7, 2026 10:45am

Novo Nordisk makes Omnicom agency of record for US media buying

Aug 7, 2026 9:44am

Fierce Biotech

Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth

Aug 7, 2026 9:08am

Amid struggles of Lilly's Foundayo, injectables still on a roll

Aug 5, 2026 11:42am

Novo CEO stands firm on guidance amid Wegovy pill sales onslaught

Aug 5, 2026 11:20am